Psoriasis Drugs Market accounted for US$ 15.85 billion in 2020 and is estimated to be US$ 37.07 billion by 2030 and is anticipated to register a CAGR of 8.90%. Growing awareness regarding disease, rising number of reimbursement strategies for biologics, and advanced technological and diagnostic tools are likely to increase the adoption of the global psoriasis drugs market. In 2016, according to the World Health Organization (WHO), psoriasis had affected at least 100 million individuals globally. Also, expanding the base of patients suffering from psoriasis is expected to propel the growth of the target market during the forecast period. As per the International Federation of Psoriasis Associations (IFPA), approximately 3% of the global population has psoriasis. Thus, it is projected to gain more share value over the forecast period. Further, with the increasing Food and Drug Administration (FDA) approval for the new drugs and therapies for the psoriasis disease is expected to surge the growth of the global market to a significant extent. Besides, to tap into an emerging market, the manufacturer is constantly improving product pipeline and the rising awareness of psoriasis and its treatment in developing countries which in turn is boosting the growth of the target market.

The report " Global Psoriasis Drugs Market, By Type (Inorganic Pigments and Organic Pigments), By Application (Packaging, Consumer Goods, Building & Construction, and Automotive), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Trends, Analysis and Forecast till 2030”

Key Highlights:

• In November 2022, Dermavant has launched first streaming commercial for new psoriasis topical skin drug ‘Vtama’. Newly launch is its first streaming commercial as part of multimedia campaign targeting adults with plaque psoriasis. The streaming video will be appearing on multimedia platforms such as Roku, YouTube and Paramount along with the radio and other social media channels.
• In September 2022, Bristol Myers Squibb new drug ‘Sotyktu’ (deucravactinib), is approved by US FDA for oral treatment for adults who are having moderate to severe plaque Psoriasis. Newly approved Sotyktu is a first in class, selective, oral, allosteric tyrosine kinase 2 (TYK2) inhibitor.

Key Market Insights from the report:        

The market report has been segmented based on therapeutic class, treatment, and region.

• By therapeutic class, Interleukin inhibitors are expected to witness the fastest growth over the forecast period, owing to the factors aiding these Interleukin inhibitors such as improved efficacy and safety when compared to other psoriasis drugs. Additionally, increased adoption among end users globally. Drugs like Ustekinumab and Secukinumab, and others, are boosting market growth as the usage of drugs is growing each year.
• By treatment, the topicals treatment segment in psoriasis drugs market is projected to be the dominant segment holding a maximum share in the global psoriasis drugs market as they are mostly favoured by the patients. Topical psoriasis drugs are applied to the skin easily and are generally the first line of defence in treating psoriasis. Topicals normalize excessive cell reproduction and reduce psoriasis inflammation. Topicals are lotions, gels, ointments, creams, and shampoos.
• By region, North America estimates for highest share in the global psoriasis drugs market owing to various acquisitions and mergers taking place in the global psoriasis drugs industry.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Psoriasis Drugs Market”, By Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, and Vitamin D Analogues), By Treatment (Topicals, Systemic, and Biologics), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030”

To know the upcoming trends and insights prevalent in this market, click the link below:

https://prophecymarketinsights.com/market_insight/Global-Psoriasis-Drugs-Market-By-70

The prominent player operating in the global psoriasis drugs market includes AbbVie, Inc., Pfizer Inc., Novartis, Eli Lilly and Company, Johnson & Johnson, Celgene Corporation, Amgen Inc., Boehringer Ingelheim GmbH, Merck & Co Inc., and Janssen Biotech Inc.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Sales

Prophecy Market Insights

Email- sales@prophecymarketinsights.com